Literature DB >> 25030930

Purification of recombinant 2XMBP tagged human proteins from human cells.

Ryan Jensen1.   

Abstract

The ability to purify an intact, functional protein or protein complex is an essential step in biochemical characterization studies. Challenges in purification arise when proteins are of low abundance or are unstable resulting in low yields or poor in vitro activity. In this protocol we describe a method to purify active, recombinant human proteins fused to a tandem MBP tag after expression in human 293T cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25030930     DOI: 10.1007/978-1-4939-0992-6_17

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  5 in total

1.  POLθ-mediated end joining is restricted by RAD52 and BRCA2 until the onset of mitosis.

Authors:  Marta Llorens-Agost; Michael Ensminger; Hang Phuong Le; Anugrah Gawai; Jie Liu; Andrés Cruz-García; Sarita Bhetawal; Richard D Wood; Wolf-Dietrich Heyer; Markus Löbrich
Journal:  Nat Cell Biol       Date:  2021-10-06       Impact factor: 28.213

2.  Distinct binding of BRCA2 BRC repeats to RAD51 generates differential DNA damage sensitivity.

Authors:  Gouri Chatterjee; Judit Jimenez-Sainz; Thomas Presti; Tiffany Nguyen; Ryan B Jensen
Journal:  Nucleic Acids Res       Date:  2016-04-15       Impact factor: 16.971

3.  A cell-penetrating antibody inhibits human RAD51 via direct binding.

Authors:  Audrey Turchick; Denise C Hegan; Ryan B Jensen; Peter M Glazer
Journal:  Nucleic Acids Res       Date:  2017-11-16       Impact factor: 16.971

4.  Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells.

Authors:  Audrey Turchick; Yanfeng Liu; Weixi Zhao; Inessa Cohen; Peter M Glazer
Journal:  Oncotarget       Date:  2019-02-12

5.  BRCA2 BRC missense variants disrupt RAD51-dependent DNA repair.

Authors:  Judit Jimenez-Sainz; Joshua Mathew; Gemma Moore; Sudipta Lahiri; Jennifer Garbarino; Joseph P Eder; Eli Rothenberg; Ryan B Jensen
Journal:  Elife       Date:  2022-09-13       Impact factor: 8.713

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.